No profile data available.
Tarsus Pharmaceuticals, Inc. (TARS) is a healthcare company in the additional infection treatment pharmaceuticals industry, based in Irvine, United States, with about 370 full-time employees.
It reported revenue of $451.36 million for fiscal year 2025, up 146.7% from fiscal year 2024, and net income of -$66.42 million. Its market capitalization was $3.42 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Tarsus Pharmaceuticals reported $451.36 million in revenue for fiscal year 2025, up 146.7% from $182.95 million in fiscal year 2024.
$3.42 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional infection treatment pharmaceuticals) include Scynexis, Inc. (SCYX), Daré Bioscience, Inc. (DARE), Pulmatrix, Inc. (PULM), 60 Degrees Pharmaceuticals, Inc. (SXTP).